Since the two first joined forces in oncology three years ago, Tempus is expanding its cancer programs with plans to acquire Personalis.
Tempus, with a total enterprise value of $1.5 billion, will acquire Personalis and capitalize on the first transaction with the company, dating back to 2023.
In the first deal, Tempus invested in Personalis and also marketed its own NeXT Personal minimal residual disease (MRD) test, a liquid biopsy for cancer.
This test can identify trace amounts of tumour DNA, which may help determine the effectiveness of cancer treatment and detect signs of any remaining or returning cancer.
Tempus will now take full control of that test and the rest of Personalis’ tech as it seeks to bolster its reach in the long-term cancer monitoring business. This will dovetail into Tempus’ AI tech approach that uses data from patients to help doctors and biopharmas find and create new meds and bolster patient care.
Eric Lefkofsky, CEO of Tempus, said in a statement that “MRD is a big and ever-growing market and could truly revolutionize the way that cancer patients are monitored, allowing for more timely and informed decisions to be made in cases of recurrence.”
As we already have a strong partnership with Personalis, we have already proven the power of using these highly sensitive MRD technologies together with our commercial infrastructure.” The momentum for clinical adoption and reimbursement has been growing and, as a group, we are well positioned to take advantage of this opportunity, making this an exciting acquisition for us.
In the second quarter, Personalis sold $22.4 million, with a 33% rise in clinical test volumes compared to Q1, the company said in a statement.
Tempus has announced the acquisition of Personalis, a leading cancer genomics specialist, in a transaction valued at approximately $1.5 billion. The deal represents a major step in Tempus’ strategy to expand its precision medicine capabilities by combining advanced genomic sequencing with artificial intelligence and clinical data analytics.
Why the Tempus Acquisition Matters
The acquisition strengthens Tempus as a leader in precision oncology by adding Personalis’ expertise in cancer genome sequencing and molecular diagnostics. The combined organization is expected to accelerate biomarker discovery, improve cancer detection, and support the development of personalized treatment strategies for patients worldwide.
The acquisition of Personalis by Tempus in a transaction valued at approximately $1.5 billion represents one of the most significant developments in the precision oncology market. As cancer care increasingly relies on genomic data and artificial intelligence, the combination of these two companies has the potential to accelerate innovation in diagnostics, clinical research, and personalized treatment strategies. The deal reflects the growing importance of integrating advanced sequencing technologies with large-scale clinical data to improve healthcare outcomes.
Overview of the Acquisition
The acquisition brings together two organizations with complementary strengths. Tempus has built a reputation for combining artificial intelligence with clinical and molecular data, while Personalis is recognized for its expertise in comprehensive cancer genome sequencing and advanced diagnostic technologies.
By merging these capabilities, the combined company aims to create a more comprehensive platform for oncologists, researchers, pharmaceutical companies, and healthcare providers. The transaction also strengthens its position in the rapidly expanding precision medicine market, where demand for genomic testing continues to rise.
Strengthening Precision Oncology
Precision oncology focuses on tailoring cancer treatments based on the unique genetic characteristics of each patient’s tumor. Rather than relying solely on traditional treatment approaches, physicians increasingly use genomic information to identify mutations that can be targeted with specific therapies.
The acquisition enhances capabilities in several areas, including:
- Comprehensive genomic profiling
- Molecular diagnostics
- Biomarker discovery
- Personalized treatment recommendations
- Clinical trial patient matching
- AI-assisted clinical decision support
These combined resources could help physicians make faster and more informed treatment decisions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
